Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) CEO Sushil Patel sold 49,026 shares of the firm’s stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $21.60, for a total value of $1,058,961.60. Following the sale, the chief executive officer directly owned 659,125 shares in the company, valued at approximately $14,237,100. This trade represents a 6.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Replimune Group Price Performance
NASDAQ:REPL opened at $19.07 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 7.11 and a quick ratio of 6.90. The company’s 50-day moving average price is $15.34 and its 200-day moving average price is $10.35. Replimune Group, Inc. has a twelve month low of $1.50 and a twelve month high of $23.54.
Replimune Group (NASDAQ:REPL – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.24. On average, research analysts expect that Replimune Group, Inc. will post -2.38 earnings per share for the current year.
Hedge Funds Weigh In On Replimune Group
Wall Street Analysts Forecast Growth
REPL has been the topic of a number of recent analyst reports. Leerink Partners boosted their price objective on Replimune Group from $19.00 to $31.00 and gave the stock an “outperform” rating in a research note on Thursday, October 29th. Wall Street Zen upgraded shares of Replimune Group from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price on the stock in a report on Friday, August 7th. Wolfe Research upgraded Replimune Group to an “outperform” rating in a research note on Tuesday, August 4th. Finally, Piper Sandler increased their price objective on Replimune Group from $14.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, November 16th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.17.
Check Out Our Latest Report on REPL
Replimune Group Company Profile
Replimune Group is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer. The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches.
See Also
- Five stocks we like better than Replimune Group
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
